227,579
Participants
Start Date
November 30, 2016
Primary Completion Date
November 30, 2016
Study Completion Date
November 30, 2016
Apixaban (ATC B01AF02)
Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
Dabigatran (ATC B01AE07)
Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
Rivaroxaban (ATC B01AF01)
Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
Centre de recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal
Drug Safety and Effectiveness Network, Canada
OTHER
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
Canadian Network for Observational Drug Effect Studies, CNODES
OTHER